Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia

Journal of Alzheimer's Disease

Volumn 43, Issue 3, 2015, Pages 949-955

  Liu Seifert, Hong ^a   Siemers, Eric ^a   Sundell, Karen ^a   Price, Karen ^a   Han, Baoguang ^a   Selzler, Katherine ^a   Aisen, Paul ^b   Cummings, Jeffrey ^c   Raskin, Joel ^a   Mohs, Richard ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

Author keywords

Activities of daily living; Alzheimer's disease; clinical trials; cognition; correlation of data; dementia; Phase 3; solanezumab

Indexed keywords

PLACEBO; SOLANEZUMAB; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ACTIVITIES OF DAILY LIVING SCALE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; FUNCTIONAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; CLINICAL TRIAL; COGNITION DISORDERS; DISEASE COURSE; DRUG EFFECTS; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; PSYCHOLOGY;

ACTIVITIES OF DAILY LIVING; ALZHEIMER DISEASE; ANTIBODIES, MONOCLONAL, HUMANIZED; COGNITION; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; NEUROPSYCHOLOGICAL TESTS;

EID: 84914674657     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140792     Document Type: Article

References (24)

1. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
2. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
3. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292.
4. Zahodne LB, Manly JJ, MacKay-Brandt A, Stern Y (2013) Cognitive declines precede and predict functional declines in aging and Alzheimer's disease. PLoS One 8, e73645.
5. Benke T, Delazer M, Sanin G, Schmidt H, Seiler S, Ransmayr G, Dal-Bianco P, Uranüs M, Marksteiner J, Leblhuber F, Kapeller P, Bancher C, Schmidt R (2013) Cognition, gender, and functional abilities in Alzheimer's disease: How are they related J Alzheimers Dis 35, 247-252.
6. Park KW, Pavlik VN, Rountree SD, Darby EJ, Doody RS (2007) Is functional decline necessary for a diagnosis of Alzheimer's disease Dement Geriatr Cogn Disord 24, 375-379.
7. Hansen RA, Gartlehner G, Lohr KN, Kaufer DI (2007) Functional outcomes of drug treatment in Alzheimer's disease. A systematic review and meta-analysis. Drugs Aging 24, 155-167.
8. Rockwood K (2007) The measuring, meaning and importance of activities of daily living (ADLs) as an outcome. Int Psychogeriatr 19, 467-482.
9. Bowie CR, Leung WW, Reichenberg A, McClure MM, Patterson TL, Heaton RK, Harvey PD (2008) Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry 63, 505-511.
10. Velligan DI, Mahurin RK, Diamond PL, Hazleton BC, Eckert SL, Miller AL (1997) The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr Res 25, 21-31.
11. Marangell LB, Clauw DJ, Choy E, Wang F, Shoemaker S, Bradley L,Mease P,WohlreichMM(2011) Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: Secondary analyses of four pooled randomized controlled trials of duloxetine. Pain 152, 31-37.
12. Raskin J,Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, Rotz BT, Mohs RC (2007) Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: An 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 164, 900-909.
13. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ (2004) A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 50, 2974-2984.
14. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141, 1356-1364.
15. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ (1997) Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's disease assessment scale that broaden its scope. Alzheimer Dis Assoc Disorder 11, S13-S21.
16. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 11, S33-S39.
17. Galasko D, Kershaw PR, Schneider L, Zhu Y, Tariot PN (2004) Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease. J Am Geriatrics Soc 52, 1070-1076.
18. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R, Alzheimer's Disease Cooperative Study Steering Committee, Solanezumab Study, Group (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 370, 311-321.
19. Ard MC, Galasko DR, Edland SD (2013) Improved statistical power of Alzheimer clinical trials by item-response theory: Proof of concept by application to the activities of daily living scale. Alzheimer Dis Assoc Disord 27, 187-191.
20. Green CR, Mohs RC, Schmeidler J, Aryan M, Davis KL (1993) Functional decline in Alzheimer's disease: A longitudinal study. JAGS 41, 654-661.
21. Garrett M, Fitzmaurice N, Laird M, Ware JH (2004) Applied Longitudinal Analysis. JohnWiley&Sons, Inc., pp. 326-328.
22. Ishizaki T, Yoshida H, Suzuki T, Watanabe S, Niino N, Ihara K, Kim H, FujiwaraY, Shinkai S, ImanakaY(2006) Effects of cognitive function on functional decline among communitydwelling non-disabled older Japanese. Arch Gerontol Geriatr 41, 47-58.
23. Amano H, Fukaya T, Liang J, Uchida H, Shinkai S (2008) Predictors of improvement or decline in instrumental activities of daily living among community-dwelling older Japanese. Gerontology 54, 373-380.
24. Njegovan V, Hing MM, Mitchell SL, Molnar FJ (2001) The hierarchy of functional loss associated with cognitive decline in older persons. J Gerontol A Biol Sci Med Sci 56, M683-M643.